Literature DB >> 19500554

Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.

Irine-Ikbale Sakou1, Georgina Tzanakaki, Maria N Tsolia, Maria Sioumala, Anastasia Barbouni, Miltiades Kyprianou, Vana Papaevangelou, Artemis Tsitsika, Caroline C Blackwell, Dimitris Kafetzis, Jenny Kremastinou.   

Abstract

Serogroup C meningococcal conjugate vaccines were introduced in Greece in 2001, and although no cases of serogroup C meningococcal disease were recorded in 2004, a steady increase was observed since 2005. In this study, serum bactericidal activity was assessed in sera of 269 vaccinated children at a mean time of about 5 years after vaccination. Non-protective antibody titers were observed in most children vaccinated at age <6 years (85.9%), followed by those between 6 and 10 years (62.2%). This percentage was considerably lower in adolescents vaccinated at an age >10 years (37.8%) (p<0.01). Geometric mean concentrations of serum IgG antibodies against serogroup C showed a similar variation. The results indicate that serum bactericidal antibody titers significantly correlate with age of vaccination; most children do not have protective antibody titers few years after immunization in infancy and childhood whereas most adolescents maintain sustained protection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500554     DOI: 10.1016/j.vaccine.2009.05.047

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.

Authors:  A Khatami; A Peters; H Robinson; N Williams; A Thompson; H Findlow; A J Pollard; M D Snape
Journal:  Clin Vaccine Immunol       Date:  2011-10-28

Review 2.  Meningococcal vaccines: current issues and future strategies.

Authors:  Amanda C Cohn; Lee H Harrison
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

3.  Vaccination coverage among adolescents and risk factors associated with incomplete immunization.

Authors:  Irine-Ikbale Sakou; Artemis K Tsitsika; Vassiliki Papaevangelou; Eleni C Tzavela; Donald E Greydanus; Maria N Tsolia
Journal:  Eur J Pediatr       Date:  2011-04-05       Impact factor: 3.183

4.  Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy.

Authors:  Arianna Neri; Massimo Fabiani; Anna Maria Barbui; Caterina Vocale; Alessandro Miglietta; Cecilia Fazio; Anna Carannante; Annapina Palmieri; Paola Vacca; Luigina Ambrosio; Paola Stefanelli
Journal:  Vaccines (Basel)       Date:  2022-05-14

5.  Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.

Authors:  Richarda M de Voer; Liesbeth Mollema; Rutger M Schepp; Sabine C de Greeff; Pieter G M van Gageldonk; Hester E de Melker; Elisabeth A M Sanders; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

6.  Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Rutger M Schepp; Ger T Rijkers; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

7.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

8.  Meningococcal Carriage in Military Recruits and University Students during the Pre MenB Vaccination Era in Greece (2014-2015).

Authors:  Kyriaki Tryfinopoulou; Konstantinos Kesanopoulos; Athanasia Xirogianni; Nektarios Marmaras; Anastasia Papandreou; Vassiliki Papaevangelou; Maria Tsolia; Aftab Jasir; Georgina Tzanakaki
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 9.  Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.

Authors:  Manish Sadarangani
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

10.  Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.

Authors:  Georgina Tzanakaki; Eva Hong; Konstatinos Kesanopoulos; Athanasia Xirogianni; Stefania Bambini; Luca Orlandi; Maurizio Comanducci; Alessandro Muzzi; Muhamed-Kheir Taha
Journal:  BMC Microbiol       Date:  2014-04-29       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.